UBS Am, A Distinct Business Unit of UBS Asset Management Americas Adds $36M in Astera Labs, Inc. ($ALAB)
UBS Am raised its position in Astera Labs by 12.7%, now holding 649,191 shares.
Key Points
- UBS Am added 72,910 shares of Astera Labs, growing its stake by 12.7% to 649,191 shares valued at $320.96 million.
- Astera Labs, a semiconductor company, has a market cap of $82.79 billion and trades near its 52-week high of $499.48.
- Analysts from firms like UBS and Stifel maintained ratings with varied price targets, reflecting diverse views on Astera Labs' potential.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
UBS Am, a business unit of UBS Asset Management Americas, has increased its stake in Astera Labs, Inc. (NasdaqGS: ALAB) by 12.7%, according to its latest 13F filing with the SEC. The firm added 72,910 shares, bringing its total to 649,191 shares, with a reported value of approximately $320.96 million as of the reporting period.
UBS Am, A Distinct Business Unit of UBS Asset Management Americas vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in UBS Am's Astera Labs Position
UBS Am boosted its holdings in Astera Labs by 12.7%, adding 72,910 shares to its portfolio. This brings the total number of shares held to 649,191, valued at about $320.96 million. The move reflects UBS Am's increased confidence in the semiconductor company.
Other Institutional Activity in Astera Labs
Several other institutional investors also adjusted their positions in Astera Labs. FMR LLC increased its holdings by 194,944 shares, bringing its total to 25,529,885 shares worth about $2.80 billion, marking a 0.8% increase. BlackRock, Inc. reduced its stake by 1,519,089 shares, now holding 11,449,769 shares valued at $1.25 billion, a decrease of 11.7%. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, with 7,309,778 shares valued at $801.15 million and 6,340,732 shares worth $694.94 million, respectively. Atreides Management, LP more than doubled its holdings, adding 1,754,593 shares for a total of 3,365,787 shares, a 108.9% increase, valued at $368.89 million. State Street Corp also grew its position by 233,797 shares, ending with 3,333,606 shares worth $365.36 million, a 7.5% increase.
Astera Labs, Inc. Stock Up 70.8%
Shares of Astera Labs (NasdaqGS: ALAB) traded near $494.4 on Wednesday. The company, with a market cap of approximately $82.79 billion, has a P/E ratio of 330.8 and a forward P/E of 112.1, indicating high growth expectations. Its beta is 3.963, suggesting significant volatility. The stock has traded between $85.85 and $499.48 over the past 52 weeks. Astera Labs' 50-day moving average is $288.50, and its 200-day moving average is $192.55. The company maintains a strong financial position with a current ratio of 11.3 and a quick ratio of 10.55, alongside a debt-to-equity ratio of 2.801.
$ALAB stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Astera Labs reported revenue of $1.00 billion, with a robust growth rate of 93.4%. The company's net margin stands at 26.7%, and it achieved a return on equity of 21.1%. Earnings per share were reported at $1.46. The next earnings release is scheduled for August 4, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
10 analysts raised price targets.
-
EPS & revenue
EPS beat estimates by 11.6%. Revenue beat estimates by 3.5%.
-
Profit surprise
EBITDA missed by 34 percent. Operating income missed by 40 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
10 target raises.
-
Earnings quality
Gross margin up 1.4 points. Operating margin up 13.0 points.
Earnings Call Summary
Astera Labs delivered strong Q1 results with revenue of $308 million, up 93 percent year over year, driven by broad growth across signal conditioning and fabric switch products. PCIe Gen 6 products contributed over one third of total revenue. The company shipped initial production volumes of the new Scorpio X 320-lane switch and is expanding optical capabilities through the XScale acquisition, with near-package optics expected to ship in 2027 and chiplet-package optics in 2028.
Guidance Management expects revenue between $355 million and $365 million in the next quarter, up 15 to 18 percent sequentially. They expect non-GAAP earnings per share between $0.68 and $0.70, with gross margin around 73 percent before a one-time customer agreement charge. The Scorpio product line is expected to become their largest business by year end.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Astera Labs, Inc.
Recent insider activity at Astera Labs includes planned sales and acquisitions. On June 24, 2026, Bethany Mayer sold 686 shares at an average price of $395.04 under a Rule 10b5-1 plan. On June 4, 2026, Jack Lazar sold 10,000 shares at $355.17, also under a planned transaction. On the same day, insiders Craig Barratt, Michael Hurlston, and Bethany Mayer each acquired 837 shares without a specified price.
Analysts Set New Price Targets
Analysts have varied opinions on Astera Labs. On June 29, 2026, UBS maintained a 'hold' rating with a $400 target. Stifel, on June 24, 2026, maintained a 'buy' rating with a $460 target. B of A Securities, on June 23, 2026, held a 'hold' rating with a $450 target. The consensus is a 'buy' recommendation with a mean target price of $272.47, based on 22 analyst opinions.
About Astera Labs, Inc.
Astera Labs, Inc. is a technology company specializing in semiconductor-based connectivity solutions for cloud and AI infrastructure. Headquartered in San Jose, California, and led by CEO Jitendra Mohan, the company employs 756 people. Its product offerings include high-speed connectivity products and software solutions that optimize resource management for large-scale cloud infrastructures.
Bottom Line
UBS Am's recent increase in its stake in Astera Labs highlights continued institutional interest in the company. Astera Labs' robust revenue growth and strong market position in the semiconductor industry make it a company worth watching. As always, it's important to remember that 13F filings are backward-looking and may not reflect current positions.
Get Astera Labs, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ALAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.